A short social post from CPOHealth on how GLP-1 drugs lower appetite and blood sugar, with a reminder that side effects come with them.
Recap by typeshit. Post by CPOHealth on X.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
The poster argues Mounjaro and Zepbound are getting easier to obtain and that coaches should watch for them on their teams. Only a short excerpt is available.
Piotr Alvarez lays out a three-stage outlook for AI in peptide method development, and the panel argues scientists keep the final judgment as conjugates get more complex.
Loading…